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T
he actin cytoskeleton powers a vari-
ety of processes, from cell migra-
tion to intracellular membrane 
transport. Pathogens often harness their 
host’s actin network to their own ends, hi-
jacking the cytoskeleton to drive cell entry, 
survival, and intercellular spread. Matthew 
Welch studies the many different mecha-
nisms that host cells and pathogens use to 
initiate actin fi  lament assembly at the right 
time and place.
Welch fi  rst became interested in actin as 
a graduate student with David Drubin at the 
University of California, Berkeley, where he 
used genetics to look for actin-interacting 
proteins in yeast (1). During his postdoc 
with Tim Mitchison at the University of 
California, San Francisco, Welch identifi  ed 
the Arp2/3 complex as the host factor that 
nucleates branched actin assembly on the 
surface of invasive Listeria to power bacte-
rial movement through the cytoplasm (2) 
and found that the same complex is present 
in lamellipodia (3).
Since his return to Berkeley to start his 
own laboratory, Welch has continued to 
work on the Arp2/3 complex (4) and the 
various nucleation-promoting 
factors that stimulate Arp2/3 
activity at different locations 
within the cell (5, 6). He’s also 
continued to study how patho-
gens subvert actin dynamics, 
recently demonstrating that 
Rickettsia species express a 
formin-like protein to nucleate 
unbranched actin fi  laments 
which drive bacterial locomo-
tion (7) and that certain viruses 
also can move with the help of their host’s 
actin cytoskeleton (8). In a recent interview, 
we asked Welch what fi  rst nucleated his in-
terest in actin and where his research inter-
ests are propelling him next.
NUCLEATING INTEREST
Where did you grow up?
I grew up in a town called Mt. Kisco in 
Westchester County, New York. My parents 
still live there. My father was a statistician 
who worked for IBM at the Thomas J. 
Watson Research Center. I used to go into 
work with him and although he didn’t work 
in a laboratory himself—he was more in-
volved in the computing side of things—
there were several laboratories in the build-
ing. So I kind of grew up around science. In 
high school I was interested primarily in 
chemistry because I had a really good teach-
er. But I also liked biology and physics.
How did you ﬁ  rst get interested in actin?
I didn’t know anything about actin or the 
cytoskeleton until I got to Berkeley for grad 
school. I’d been a molecular and cell biol-
ogy major at the University of Michigan, 
but I’d never actually taken a cell biology 
course. In fact, I didn’t take a cell biology 
class at Berkeley either, even though I teach 
one there now! But David Drubin, who was 
a new faculty member at the time, gave a 
great seminar about yeast actin. And I de-
cided to rotate in his laboratory.
At that time it was clear that yeast had a 
cytoskeleton, but it wasn’t so clear what they 
did with it. However, yeast had the genetic 
tools available to really dissect what the cy-
toskeleton does in eukaryotes. So I did a ge-
netic screen to look for actin-
interacting proteins. A simi-
lar type of screen had already 
been used for tubulin, so we 
thought it was a good idea to 
try it with actin as well. But it 
didn’t really work out in that 
we didn’t identify any pro-
teins that directly regulate 
actin dynamics. Neverthe-
less, I ended up identifying a 
nuclear protein that turned 
out to be part of a transcription regulatory 
complex. That’s kind of interesting because 
actin is now known to function in the nucle-
us in transcription and chromatin remodel-
ing processes. But at the time it was a little 
bit unclear what the two proteins had to do 
with each other.
BRANCHING OUT
Why did you choose Tim Mitchison’s 
laboratory for your postdoc?
Tim and one of his graduate students, Julie 
Theriot, had both come to give seminars at 
Berkeley. Looking at actin dynamics in 
yeast was technically diffi  cult at that time, 
but Tim and Julie had done some really 
beautiful work developing caged actin de-
rivatives that they could photo-activate and 
use to monitor actin dynamics in mamma-
lian cells. It was really exciting.
Julie had also started using Listeria as a 
model system and shown that actin dy-
namics in Listeria comet tails were very 
similar to those in lamellipodia. At the 
time, people had identifi   ed many actin-
binding proteins, but none of them seemed 
to be good candidates for nucleating actin 
in the cell. So I was really interested in 
identifying the proteins that nucleated ac-
tin assembly in both the Listeria “tail” and 
the lamellipodium.
Genetic approaches had already identi-
fi  ed a Listeria protein that was necessary 
for actin nucleation. But it wasn’t suffi  cient, 
so I set out to purify the host proteins in-
volved. It was a long haul, and at various 
points I wasn’t sure I was going to be suc-
cessful. But eventually I decided to recon-
stitute Listeria motility in human platelet 
extract instead of the Xenopus egg extract 
that Julie Theriot had pioneered. That 
turned out to be a better starting material 
because it was very rich in cytoskeletal pro-
teins, and that allowed me to purify and 
identify the Arp2/3 complex as the factor 
that nucleated actin at the Listeria surface.
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Welch investigates how host cells and pathogens initiate actin polymerization.
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“Arp2/3 
activity has to 
be harnessed 
in different 
places and 
times in the 
cell.”
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You’ve investigated the Arp2/3 complex 
ever since. What are the most important 
remaining questions?
One thing that’s really hindered our under-
standing of the mechanism of actin nuclea-
tion is that it’s been very diffi  cult to get a high 
resolution structure of the Arp2/3 complex in 
its fully activated form, where it’s bound to a 
nucleation-promoting factor or in the branch 
point between two actin fi  laments. So I think 
the structural and mechanistic side of things 
is where we really have to make progress.
Why are there so many different 
nucleation-promoting factors that activate 
the Arp2/3 complex?
I think it’s because Arp2/3 activity has to be 
harnessed in different places and times in 
the cell. Each organelle seems to require a 
specifi  c factor that nucleates actin polym-
erization and adapts actin’s function to that 
particular location. For example, we recent-
ly identifi  ed a nucleation-promoting factor 
called WHAMM, which is required for 
membrane transport to and from the Golgi. 
It’s an interesting molecule because, as well 
as regulating actin by activating Arp2/3, it’s 
also a microtubule-binding protein.
HIJACKING THE CYTOSKELETON
How and why do pathogens co-opt the 
Arp2/3 complex?
One example is during the entry process. 
Phagocytosis and endocytosis both involve 
actin, so most intracellular pathogens need to 
activate actin polymerization during entry. 
Some bacteria inject proteins into the host cell 
through secretion systems to activate signal-
ing pathways or nucleate actin directly. Other 
pathogens express molecules that bind host 
surface receptors to trigger actin assembly.
Once they are in the cell, pathogens face 
another problem, which is how to get back 
out of the cell after they’ve replicated. That’s 
where pathogens such as Listeria or Shigel-
la use actin-based motility. They’re good 
mimics. Listeria express the protein ActA, 
which directly mimics the host’s nucleation-
promoting factors to activate Arp2/3. Shi-
gella, on the other hand, mimic the signal-
ing pathways that activate the host factor 
N-WASP and use it to stimulate Arp2/3.
You recently showed that Rickettsia species 
use a different mechanism entirely…
We think they don’t use Arp2/3, at least for 
steady-state movement. Instead, they make 
their own formin-like protein called Sca2 to 
generate parallel, rather than branched, ac-
tin arrays that drive intracellular motility. I 
don’t know why Rickettsia use a different 
strategy, but I think it’s a really intriguing 
question. Rickettsia naturally infect cells in 
ticks as their primary reservoir, but then 
they also infect mammalian cells. It’s pos-
sible that the formin-type mechanism better 
adapts them to movement in such diverse 
cell types: a formin can directly polymerize 
actin, whereas a nucleation-promoting fac-
tor has to interface with Arp2/3, which then 
interacts with actin.
The other interesting thing is that there’s 
a broad diversity of Rickettsia species, some 
of which express a very similar version of 
the formin-like protein Sca2 and cause dis-
eases like Rocky Mountain spotted fever. 
But more distantly related Rickettsia species 
have very different Sca2 proteins that may 
not function like a formin. They may func-
tion like an Arp2/3 activator or an actin nu-
cleator similar to the Drosophila protein 
Spire. So within a single group of bacteria, 
there’s a plausible evolutionary progression 
of actin-based motility mechanisms.
You also investigate baculoviruses. Why 
are you interested in these pathogens?
Baculoviruses do really interesting things 
with actin. They use it for intracellular move-
ment—which is different from other viruses, 
which normally use microtubules. But the 
really intriguing thing about baculoviruses is 
that they can move actin into the nucleus and 
polymerize it there. So they re-compartmen-
talize the cytoskeleton. Actin is naturally 
present in the nucleus, but its function there 
is poorly understood. Baculoviruses might 
offer us a window into the potential nuclear 
functions of actin because they may be exag-
gerating an existing function for actin rather 
than inventing a new one.
We pick pathogens to work on not be-
cause they’re necessarily important causes of 
disease, but because they have interesting 
ways of interacting with actin. It’s a little bit 
of a cliché at this point, but people say that 
pathogens are the best cell biologists because 
they’ve evolved over the years to exploit the 
workings of the cell. So they offer a window 
into how things work, and they’re often easy 
to manipulate biochemically and genetically.
What are you working on at the moment?
We’re continuing to focus on Rickettsia and 
baculoviruses. We’re interested in explor-
ing the evolution of actin-based pathogen 
motility by examining the different Rickett-
sia species. And for baculoviruses we’re 
looking at the function of nuclear actin as-
sembly. They may use it for replication or 
for completion of packaging and escape 
from the nucleus. Away from pathogens, 
we’re investigating how nucleation-pro-
moting factors direct Arp2/3 activity to dif-
ferent locations and processes in the cell.
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Baculovirus particles (red) are propelled 
through their host’s cytoplasm by polymerizing 
actin (green).
“Baculoviruses… 
re-compartmentalize 
the cytoskeleton.”
WASH (green) stimulates the nucleation of actin 
ﬁ  laments (red) to regulate endosomal trafﬁ  cking.
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